Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Lumos Pharma (NASDAQ:LUMO) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The company will present a pre-recorded session starting at 7:00 AM (EDT) on September 12. Additionally, management will hold one-on-one meetings during the event. Lumos Pharma is advancing its lead candidate, LUM-201, currently in Phase 2 trials for Pediatric Growth Hormone Deficiency (PGHD). If approved, LUM-201 would offer an oral alternative to current injection treatments.

AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the H.C. Wainwright 24^th Annual Global Investment Conference in September.

Event:		H.C. Wainwright 24th Annual Global Investment Conference – September 12th-14th
Presentation:		Pre-recorded presentation available beginning September 12th at 7:00 AM (EDT)
Webcast link:		Here
1x1 Meetings:		Management will be available for one-on-one meetings during the conference, September 12th-14th

The webcast for the presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section. Please contact your H.C. Wainwright salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conference or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

FAQ

When is the H.C. Wainwright 24th Annual Global Investment Conference for LUMO?

The conference will take place from September 12 to 14, 2022.

What is LUM-201 in relation to Lumos Pharma?

LUM-201 is Lumos Pharma's lead therapeutic candidate for Pediatric Growth Hormone Deficiency, currently in Phase 2 clinical trials.

What time will Lumos Pharma's presentation be available during the conference?

The pre-recorded presentation will be accessible beginning at 7:00 AM (EDT) on September 12, 2022.

How can investors schedule meetings with Lumos Pharma during the conference?

Investors can contact H.C. Wainwright salespeople or Lumos Pharma Investor Relations to schedule one-on-one meetings.

What designation has LUM-201 received in the US and EU?

LUM-201 has received Orphan Drug Designation in both the United States and the European Union.